Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the open label
extension study

2. Willing and able to comply with the study Schedule of Activities

3. Participants who have completed the full study treatment period of any prior
"Novartis sponsored" iptacopan Phase 3 clinical trial in aHUS, are still on
iptacopan study treatment and derive benefit from it as per Investigator's judgement

4. Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and
Haemophilus influenzae infections should be up to date (i.e., any boosters required
should be administered according to local guidelines)

Exclusion Criteria:

1. Concomitant treatment with any complement inhibitor as well as concomitant treatment
with any of the prohibited drugs

2. Any comorbidity or medical condition (including but not limited to any active
systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of
the Investigator could put the participant at risk

3. Active infection or history of recurrent invasive infections caused by encapsulated
bacteria such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus
influenzae

4. History of hypersensitivity to iptacopan or its excipients or to drugs of similar
chemical classes

5. Pregnant or nursing (lactating) women

6. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using effective methods of contraception during
dosing of investigational drug and for 1 week after stopping of investigational
drug.

Other protocol-defined inclusion/exclusion criteria may apply.